Is the CPS a BRCA Mutation?

The keynote 522 did not address this directly, but we have many safety data sets in the metastatic setting for combining IO with PARP inhibitor. So I would extrapolate that safety data and give both a laparab and femoralism to this particular patient. In the early state setting, PDL1 expression has no bearing on this decision. We're going to talk about a lot more like going on by specific diffuse large B cell, etc., etc. Molecular by specific so much going on.